NEX CEO Sees Opportunity for Opportunities after CME Deal
Executive says he expects CME group to continue investing in fintech startups after takeover.

On March 29, the CME made a formal offer to acquire NEX Group in a cash-and-shares deal that values NEX at around $5.4 billion (£3.9 billion).
The rationale for the deal largely centers on NEX’s electronic-trading offerings, including foreign-exchange platform EBS and BrokerTec, which is the leader in US Treasurys trading, along with NEX’s post-trade businesses including TriOptima.
However, NEX has also been aggressive in recent years investing in early-stage fintech startups through its Euclid Opportunities vehicle, now known as NEX Opportunities after NEX emerged from Icap’s sale of its voice-broking arm to rival interdealer broker Tullett Prebon in 2016.
Through that arm, NEX has made a range of investments stretching from seed capital through to Series C funding rounds in firms as varied as RSRCHXChange, OpenFin, Axoni, Cloud9, Enso, and OpenGamma.
Some of those firms have even been brought in-house. However, NEX Opportunities was not mentioned in either the initial offer released on March 29 or in slides accompanying an analyst presentation.
However, during a call with journalists held on the same day to discuss the offer, NEX Group CEO Michael Spencer said that he expects the same practice to continue in the enlarged group.
“The Nex Opportunities project we started about five or six years ago has been very effective for us, and very successful for us,” Spencer said, in response to a question from WatersTechnology. “I think it’s worth bearing in mind that [legacy] Icap funded TriOptima as a startup in 2002 when it was an idea, not even a business, and that project obviously turned out extremely well, and TriOptima is a very successful and profitable business for us. We found there has been value in this entrepreneurship, in locating and investing in startup businesses, and we expect to continue to do that.”
CME’s acquisition of NEX is subject to regulatory and shareholder approvals. Under UK takeover rules, other interested parties have 21 days to submit a counter-offer for NEX, which cannot hold a shareholder vote before that—CME shareholder approval is not required for the deal to proceed.
Brexit Bull
Assuming the various approvals are received, NEX and CME say they expect the deal to close in the second half of 2018. Following the move, the group headquarters of the enlarged CME Group will be in Chicago, while its European headquarters will be in London.
“London already is CME’s European headquarters, it will remain that way and only get bigger from a London perspective,” said CME chairman and CEO, Terry Duffy, in response to a question from WatersTechnology on the same call.
While the CME already has a significant presence in the British capital, employing several hundred people there, it has also pulled back on its European operations in recent years, closing both CME Europe and CME Clearing Europe in 2017. As such, the move is also a renewed vote of confidence in the city’s future, as the UK’s imminent departure from the European Union has seen financial services firms of all stripes set up significant operations in other European cities. This is to avoid being locked out of the single market or lose “passporting” rights after Brexit, which allow them to offer products and services throughout the bloc.
“From our point of view, and Terry and I are in complete agreement about this, notwithstanding Brexit, London is going to be the most important financial center within Europe—and this is not a pro- or anti-Brexit, politically-partisan opinion whatsoever,” said Spencer, who will become a special adviser to CME and join its board after the deal closes. “NEX has made appropriate moves to passport some of our businesses into Europe, and in any case, it has a big operation in Stockholm, a smaller operation in Milan, and we’re passporting the BrokerTec electronic platform into Amsterdam. We are absolutely not taking a Brexit view at all, but London is the right place for the enlarged CME business to headquarter itself in Europe.”
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Emerging Technologies
LSEG’s private funds platform, Microsoft’s new datacenter, and more
The Waters Cooler: New private markets solutions, M&A activity, and a sprinkle of DLT in this week’s news roundup.
BlueMatrix acquires FactSet’s RMS Partners platform
This is the third acquisition BlueMatrix has made this year.
Waters Wavelength Ep. 331: Cresting Wave’s Bill Murphy
Bill Murphy, Blackstone’s former CTO, joins to discuss that much-discussed MIT study on AI projects failing and factors executives should consider as the technology continues to evolves.
FactSet adds MarketAxess CP+ data, LSEG files dismissal, BNY’s new AI lab, and more
The Waters Cooler: Synthetic data for LLM training, Dora confusion, GenAI’s ‘blind spots,’ and our 9/11 remembrance in this week’s news roundup.
Chief investment officers persist with GenAI tools despite ‘blind spots’
Trading heads from JP Morgan, UBS, and M&G Investments explained why their firms were bullish on GenAI, even as “replicability and reproducibility” challenges persist.
Wall Street hesitates on synthetic data as AI push gathers steam
Deutsche Bank and JP Morgan have differing opinions on the use of synthetic data to train LLMs.
A Q&A with H2O’s tech chief on reducing GenAI noise
Timothée Consigny says the key to GenAI experimentation rests in leveraging the expertise of portfolio managers “to curate smaller and more relevant datasets.”
Etrading wins UK bond tape, R3 debuts new lab, TNS buys Radianz, and more
The Waters Cooler: The Swiss release an LLM, overnight trading strays further from reach, and the private markets frenzy continues in this week’s news roundup.